Details of the Drug

General Information of Drug (ID: DM1PRT6)

Drug Name

M710

Synonyms

637-01-4; N,N,N',N'-Tetramethyl-p-phenylenediamine dihydrochloride; N1,N1,N4,N4-tetramethylbenzene-1,4-diamine dihydrochloride; N,N,N',N'-Tetramethyl-1,4-phenylenediamine Dihydrochloride; UNII-66W8HKA51X; MFCD00012482; 66W8HKA51X; tetramethyl-p-phenylenediamine dihydrochloride; 1,4-Benzenediamine, N,N,N',N'-tetramethyl-, dihydrochloride; NSC36730; 1,4-Benzenediamine, N1,N1,N4,N4-tetramethyl-, hydrochloride (1:2); 1-N,1-N,4-N,4-N-tetramethylbenzene-1,4-diamine;dihydrochloride; Wursters Reagent; N,N,N',N'-Tetramethyl-p-phenylenediamine dihydrochloride, 99%; EINECS 211-274-8; NSC 36730; TMPPD; ACMC-1B8O0; SCHEMBL379125; DTXSID2060915; N,N,N',N'-Tetramethyl-para-phenylenediamine dihydrochloride; ANW-34710; AKOS005254702; MCULE-3840175847; VZ32824; AS-14819; SY061584; 3-(4-Bromo-1H-pyrazol-1-yl)propanoicacid; DB-054526; FT-0629355; ST50308398; Tetramethyl-p-phenylene diamine hydrochloride; 1,4-Bis(dimethylamino)benzene dihydrochloride; X-4255; N,N,N',N'-Tetramethyl-p-phenylenediamine 2HCl; N,N,N',N'-Tetramethyl-p-phenylenediamine DiHCl; W-104885; Q27264036; [4-(dimethylamino)phenyl]dimethylamine, chloride, chloride; N,N,N\\',N\\'-Tetramethyl-p-phenylenediamine dihydrochloride; N1,N1,N4,N4-Tetramethyl-1,4-benzenediamine Dihydrochloride; p-Phenylenediamine, N,N,N',N'-tetramethyl-, dihydrochloride (8CI); N,N,N',N'-Tetramethyl-p-phenylenediamine dihydrochloride, >=95%, powder; N,N,N',N'-Tetramethyl-p-phenylenediamine dihydrochloride, >=97.0% (AT)

Indication

Disease Entry	ICD 11	Status	REF
Diabetic macular edema	9B71.02	Phase 3	[1]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL is unavailable

2D MOL

#Ro5 Violations (Lipinski):
0

Molecular Weight

237.17

Logarithm of the Partition Coefficient

Not Available

Rotatable Bond Count

Hydrogen Bond Donor Count

Hydrogen Bond Acceptor Count

Chemical Identifiers

Formula: C10H18Cl2N2
IUPAC Name: 1-N,1-N,4-N,4-N-tetramethylbenzene-1,4-diamine;dihydrochloride
Canonical SMILES: CN(C)C1=CC=C(C=C1)N(C)C.Cl.Cl
InChI: InChI=1S/C10H16N2.2ClH/c1-11(2)9-5-7-10(8-6-9)12(3)4;;/h5-8H,1-4H3;2*1H
InChIKey: FBHKTSXMTASXFJ-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 71561
CAS Number: 637-01-4
TTD ID: D4Z5CU

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Vascular endothelial growth factor (VEGF)	TT9HKJA	VEGFA_HUMAN ; VEGFB_HUMAN ; VEGFC_HUMAN ; VEGFD_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Ly6/PLAUR domain-containing protein 6 (LYPD6)	OTT45DF7	LYPD6_HUMAN	Drug Response	[2]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	ClinicalTrials.gov (NCT03610646) Comparative Study to Evaluate the Efficacy and Safety of MYL-1701P and Eylea in Subjects With Diabetic Macular Edema. U.S. National Institutes of Health.
2	Population-based in vitro hazard and concentration-response assessment of chemicals: the 1000 genomes high-throughput screening study. Environ Health Perspect. 2015 May;123(5):458-66. doi: 10.1289/ehp.1408775. Epub 2015 Jan 13.